Topics

Private preferred share sale nets $18.35mm for Delcath

15:40 EDT 12 Jul 2019 | Elsevier Business Intelligence

Delcath Systems Inc. (liver-directed high-dose chemotherapy) netted $18.35m through a private placement of 20k preferred shar...

Original Article: Private preferred share sale nets $18.35mm for Delcath

NEXT ARTICLE

More From BioPortfolio on "Private preferred share sale nets $18.35mm for Delcath"

Quick Search

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...